Clinical Trial Update: Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule [Phase 4]

View source ↗

Summary

This Phase 4 study assesses the long-term immune persistence of GlaxoSmithKline's inactivated hepatitis A vaccine given on a 0 and 6 month schedule.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• Havrix (hepatitis A vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis A | Phase 4 | Status: COMPLETED | Results posted: 2010-03-04